Summary
Bristol Myers Squibb Company (BMY) has filed an 8-K report on January 30, 2023, announcing the departure of Dr. Rupert Vessey, Executive Vice President of Research and Early Development, effective July 3, 2023. This executive transition marks a notable change in the company's research leadership. While Dr. Vessey's departure is confirmed, the company has outlined the financial and equity arrangements associated with his exit. Investors should note the specific details regarding Dr. Vessey's severance benefits, which will be in line with the company's Senior Executive Severance Plan. Additionally, his equity awards, including Market Share Units (MSUs) and Performance Share Units (PSUs), will vest on a pro-rated basis. Notably, his 2019 Restricted Stock Units Inducement Award will vest in full. He will also receive a pro-rated annual incentive payout for 2023. These details provide transparency on the financial implications of this executive departure.
Key Highlights
- 1Dr. Rupert Vessey, EVP of Research and Early Development, is departing Bristol Myers Squibb.
- 2The departure is effective July 3, 2023.
- 3Dr. Vessey will receive severance benefits under the company's Senior Executive Severance Plan.
- 4Certain equity awards, including MSUs and PSUs, will have pro-rated vesting.
- 5Dr. Vessey's 2019 Restricted Stock Units Inducement Award will vest in full.
- 6A pro-rated annual incentive payout of $550,855 for 2023 will be provided to Dr. Vessey.